Clinical Evaluation of the PowerGlide™ Pro Midline Catheter

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06037525

Acronym

Midline

Enrollment

Registered

2023-09-14

Start date

2018-01-01

Completion date

2023-05-01

Last updated

2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter Infection, Pain

Brief summary

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases

Detailed description

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases. The selected patients are in need of a long-term i.v. therapy for reasons as antibiotic therapy or alprostadil therapy. The Midline catheter is a device, which is placed via Seldinger's technique to a vein usual on the upper extremity under ultrasound-control.

Interventions

DEVICEPowerGlide™ Pro Midline Catheter

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* need for i.v. therapy longer than 7 days * poor peripheral vein status * Administration of alprostadil

Exclusion criteria

* pending dialysis * allergy to catheter material * minor age * life threatening conditions * requirement for central venous catheter

Design outcomes

Primary

Measure	Time frame	Description
Dwelling Time	0-29 days	Length of catheter in situ time

Secondary

Measure	Time frame	Description
Administration of Alprostadil	0-29 days	Feasibility for the usage of Alprostadil measured by patients with development of thrombophlebitis or occlusion
Catheter Complications	0-29 days	Site complications as thrombophlebitis and occlusion

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026